Usual Adult Dose for Plaque Psoriasis

150 mg (two 75 mg injections) subcutaneously at Week 0, Week 4, and every 12 weeks thereafter

Comments:

• Evaluate patients for tuberculosis (TB) infection prior to initiating this drug.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• None

Dialysis

Data not available

Other Comments

Administration advice:

• This drug is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject after training in subcutaneous injection technique.
• Visually inspect the prefilled syringe for particulate matter and discoloration prior to administration. It should be a colorless to slightly yellow and clear to slightly opalescent solution. It may contain a few translucent to white particles. Do not use if the solution contains large particles or is cloudy or discolored.
• Inject 2 separate 75 mg single-dose prefilled syringes for the full 150 mg dose.
• Discard prefilled syringes after use; do not reuse.
• Administer the injections at different anatomic locations (e.g., thigh, abdomen) and not into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis. Administration into the upper outer arm may only be performed by a healthcare professional or caregiver.
• If a dose is missed, administer it as soon as possible; thereafter, resume dosing at the regular scheduled time.
• Instruct the patient that two separate 75 mg single-dose injections are required to achieve the 150 mg dose.
• The "Instructions for Use" contains more detailed instructions on the preparation and administration of this drug.

• Store unopened product in a refrigerator at 2C to 8C (36F to 46 F).
• Do not freeze.
• Do not shake.
• Keep the prefilled syringes in the outer carton to protect from light.
• Not made with natural rubber latex.

• Before injecting remove the carton from the refrigerator and allow to reach room temperature out of direct sunlight (15 to 30 minutes) without removing the prefilled syringes from the carton.
• Visually inspect the prefilled syringe for particulate matter and discoloration prior to administration. It should be a colorless to slightly yellow and clear to slightly opalescent solution. It may contain a few translucent to white particles. Do not use if the solution contains large particles or is cloudy or discolored.

• Evaluate patients for tuberculosis (TB) infection prior to initiating this drug.

• Read the 'Instructions for Use' before administration of this drug.

Frequently asked questions

• What are the new drugs for the treatment of plaque psoriasis?
• Does Skyrizi cause cancer?
• Skyrizi vs Humira for plaque psoriasis - How do they compare?
• Is Skyrizi approved for treating psoriatic arthritis?
• Who makes Skyrizi and where is it made?
• Skyrizi vs Ilumya. What’s the difference?